High-grade, large flake graphite at BlackEarth's Razafy Resource

Published 10-DEC-2018 09:53 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

A comprehensive metallurgical test work program on bulk samples from BlackEarth Minerals NL’s (ASX:BEM) Razafy Resource confirms high-grade, large flake concentrate. The Razafy Resource sits within the company’s broader Maniry Graphite Project, which covers a total of 142 square kilometres in southern Madagascar.

The Maniry Project is one of two of BEM’s 100%-owned Madagascan graphite projects, the other being the Ianapera Project in the country’s north. Maniry is highly prospective for large-scale, high-quality graphite deposits and is currently at an advanced evaluation stage. The Razafy indicated and inferred resource, comprising of 11.2Mt at 7.10% Total Graphitic Carbon (TGC).

Results, from recent diamond drilling have confirmed that the Razafy Prospect consists of high grade, thick outcropping graphitic mineralisation contained within distinct lenses which remain not only open along strike but also at depth.

Recent identification of further lenses to the east also highlights the prospectivity of the immediate area which, based on mapping and previous exploration represents only 5% of the current Maniry Project area.

A diamond core drill program was conducted in early 2018 to generate samples for metallurgical testwork. From these drill programs, sampling and compositing was undertaken to generate representative samples to assess the ore's amenability to beneficiation by froth flotation, and also to identify the nature, flake size and occurrence of the graphite in a selection of drill core samples and flotation products.

The bulk composite sample was sent to ALS Laboratory in Perth in late August 2018 with the metallurgical testwork program managed by BatteryLimits. The results, shown below, reaffirm the company’s earlier positive preliminary results announced on 16 October 2018.

Concentrate Grade and Size Distribution

A total graphitic carbon (TGC) grade of >95% TGC was obtained across the full concentrate particle (flake) size distribution and is free of deleterious materials.

Notably, 50% of the graphite concentrate is represented by a flake size over 180μm, which should enable the product to be sold into premium market segments attracting higher prices, while 20% of the product falls within the Jumbo / Super Jumbo range (>300μm).

Also notable, was that comminution results indicate low to moderate ore hardness which may potentially reduce processing costs.

These results will be used to finalise the Maniry Graphite Project’s process flow sheet and current Scoping Study, ahead of the commencement of the bankable feasibility study which is due to commence in Q1 2019.

Further samples are now being planned to allow additional testwork for downstream testwork including purification and expandability testwork; thickener tests on concentrates and tails; filtration on concentrates; tailings for Geochemistry and Geotech.

Managing Director, Tom Revy commented: “The quality and consistency in these results further strengthens the Board’s decision to commence the feasibility study in early 2019. I look forward to providing further detail on the Maniry Graphite Project in line with our expected release on Scoping Study outcomes, shortly.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X